Ipratropium Pediatric Dose — Asthma & Respiratory
Ipratropium bromide is an inhaled anticholinergic bronchodilator that works by competitively blocking muscarinic receptors in airway smooth muscle, reducing bronchoconstriction and secretions. It is used in pediatric patients as adjunctive therapy alongside beta-2 agonists (e.g., albuterol) in the management of moderate-to-severe acute asthma exacerbations. Its primary role in children is to provide additive bronchodilation during the acute phase of treatment in the emergency department or inpatient setting.
Pediatric Dosing
- Emergency Department (acute severe exacerbation): 0.5 mg inhaled every 20 minutes for 3 doses (given concurrently with short-acting beta-2 agonist nebulization)
- Maintenance/continued therapy (up to 24 hours): 0.5 mg inhaled every 6–8 hours for 24 hours
Unlike many pediatric drugs, the standard ipratropium nebulized dose of 0.5 mg is a fixed dose (not weight-based) consistent across pediatric patients in this clinical context. This reflects the unit-dose formulation (0.5 mg/2.5 mL vial) commonly used in practice. Consult institutional protocol for dosing in infants or children under 5 years of age, as some centers use lower fixed doses.
Example: A 20 kg child presenting with a severe asthma exacerbation would receive 0.5 mg nebulized every 20 minutes for 3 doses in the ED (total 1.5 mg over approximately 40–60 minutes), followed by 0.5 mg every 6–8 hours for up to 24 hours.
Indications and Clinical Context
Ipratropium is indicated as adjunctive bronchodilator therapy in pediatric patients with moderate-to-severe acute asthma exacerbations. Per PALS and GINA guidelines, ipratropium should be combined with a short-acting beta-2 agonist (SABA) in the initial management of severe exacerbations to maximize bronchodilation through complementary mechanisms. Evidence supports that early combination therapy reduces hospitalization rates compared to SABA alone in children presenting to the emergency department.
Its use is generally limited to the first 24 hours of an acute exacerbation; ipratropium is not recommended as a long-term maintenance therapy for asthma. It may also be considered in acute bronchospasm associated with other obstructive airway conditions under specialist guidance.
Administration and Monitoring
Ipratropium is administered via nebulization and may be combined in the same nebulizer cup with albuterol for simultaneous delivery, improving efficiency during acute resuscitation. The 0.5 mg unit-dose vial (0.02 mg/mL, 2.5 mL) is the standard preparation used in most emergency and inpatient settings. A metered-dose inhaler (MDI) with spacer is an acceptable alternative when the patient can cooperate.
- Route: Inhaled (nebulization or MDI with spacer)
- Adverse effects to monitor: Dry mouth, mild tachycardia, urinary retention (rare in children), and paradoxical bronchospasm (uncommon)
- Contraindications: Known hypersensitivity to ipratropium, atropine, or related alkaloids; use with caution in patients with narrow-angle glaucoma or bladder outlet obstruction
- Max duration: Limit combined ipratropium/SABA therapy to the first 24 hours of an acute exacerbation per standard practice; consult institutional protocol for extended use
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.